US stocks move: Moderna rises nearly 6% and leads vaccine-related stocks as its flu vaccine approval is imminent

Glonghui, June 23 | US vaccine concept stocks rose across the board, with Moderna up nearly 6%, Merck, AstraZeneca, GlaxoSmithKline, and Johnson & Johnson all gaining more than 2%, and Teva Pharmaceutical rising 1.7%. On the news front, the FDA's Vaccines and Related Biological Products Advisory Committee recently voted 9-0 in favor of Moderna's seasonal influenza vaccine MFLUSIVA (mRNA-1010) for use in adults aged 50-64 and elderly people aged 65 and above, recognizing its benefit-risk profile as clinically valuable. Although the final approval decision is still pending until August 5, under typical vaccine review practices, unanimous support from VRBPAC often means that there are no substantial regulatory obstacles remaining. In addition, an Ebola outbreak in the Democratic Republic of the Congo has attracted widespread attention. On June 21, the Ministry of Health of the Democratic Republic of the Congo reported that the cumulative number of confirmed cases in the current round of the Ebola outbreak in the country had risen to 1,003, of which 254 were fatal.